Clinical trial · no report yet · Phase 3
TRITON3
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
- NCT02975934 ↗
- Completed
- pharmaand GmbH
- 114 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| Podcasts | 51 | |
| X threads | 49 | |
| YouTube | 14 |
The trial
ClinicalTrials.gov- Official title
- TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- Rucaparib; Abiraterone acetate or Enzalutamide or Docetaxel
- Arms
- Rucaparib · Experimental
- Abiraterone acetate or Enzalutamide or Docetaxel · Active comparator
- Enrollment
- 405
- Primary outcomes
- Radiographic Progression-free Survival (rPFS) by IRR in Participants With a BRCA Alteration
- Radiographic Progression-free Survival (rPFS) by IRR in Participants With a BRCA or ATM Alteration Combined
- Sponsor
- pharmaand GmbH with Foundation Medicine
- Start
- Jun 13, 2017
- Primary completion
- Aug 25, 2022
- Results posted
- Yes
- Registry record
- NCT02975934 · updated Jul 25, 2025
Publications
linked from the registry- Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nole F, Staffurth J, Redfern C, Saez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH; TRITON3 Investigators. Rucaparib or Physician's Choice in Metastatic Prostate Cancer. N Engl J Med. 2023 Feb 23;388(8):719-732. doi: 10.1056/NEJMoa2214676. Epub 2023 Feb 16. PubMed 36795891
- Collins K, Cheng L. Reprint of: morphologic spectrum of treatment-related changes in prostate tissue and prostate cancer: an updated review. Hum Pathol. 2023 Mar;133:92-101. doi: 10.1016/j.humpath.2023.02.007. Epub 2023 Mar 8. PubMed 36898948
- Maia MC, Salgia M, Pal SK. Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. Nat Rev Urol. 2020 May;17(5):271-291. doi: 10.1038/s41585-020-0297-9. Epub 2020 Mar 17. PubMed 32203306